BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17022049)

  • 1. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.
    Buadi FK; Heyman MR; Gocke CD; Rapoport AP; Hakimian R; Bartlett ST; Sarkodee-Adoo C
    Am J Hematol; 2007 Mar; 82(3):208-14. PubMed ID: 17022049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
    Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
    Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
    J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S; Oertel S; LeBlond V; Riess H; Varoqueaux N; Dörken B; Trappe R
    Ann Hematol; 2007 Aug; 86(8):599-607. PubMed ID: 17522862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
    Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
    Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
    Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
    Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC
    Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
    Raj R; Frost AE
    J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.